GO:0097341Tumor vs NormalRNA activityBox plot · TCGA cohorts
Across TCGA pan-cancer cohorts, RNA activity of the Zymogen inhibition pathway differs between tumor and matched normal tissue in 10 of the 18 cancer types tested.
The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where pathway activity is higher in tumor tissue than in matched normal tissue. In most cancer types, this pathway shows higher activity in tumors, although a few cancer types, such as LUAD and LUSC, show the opposite pattern, with lower activity in tumor tissue.
KIRC, LUAD, and LUSC show the most reproducible tumor–normal differences in pathway activity.
Tumor vs normal pathway activity by lineage
Ranked by sampling consensus. Activity change represents the tumor-versus-normal difference in pathway activity on a log2 scale. Positive values indicate higher pathway activity in tumor tissue. The reported p-values are derived from the corresponding differential activity tests.